The prevailing view among regulators and industry is that, as proteins are much more complex than small molecule drugs, it is not possible to demonstrate the identical nature of two biological products arising from different manufacturing sources. Therefore, follow-on proteins produced by generic manufacturers cannot be approved as simple generics but need additional nonclinical and clinical data to demonstrate that they have an equivalent safety and efficacy profile to the originator product.
展开▼
